Q32 Bio Inc - Asset Resilience Ratio
Q32 Bio Inc (QTTB) has an Asset Resilience Ratio of 8.04% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Q32 Bio Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Q32 Bio Inc's Asset Resilience Ratio has changed over time. See Q32 Bio Inc book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Q32 Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see QTTB market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.99 Million | 8.04% |
| Total Liquid Assets | $9.99 Million | 8.04% |
Asset Resilience Insights
- Limited Liquidity: Q32 Bio Inc maintains only 8.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Q32 Bio Inc Industry Peers by Asset Resilience Ratio
Compare Q32 Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Q32 Bio Inc (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Q32 Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 92.20% | $43.39 Million | $47.06 Million | +69.77pp |
| 2021-12-31 | 22.43% | $47.49 Million | $211.72 Million | -44.74pp |
| 2019-12-31 | 67.17% | $208.61 Million | $310.57 Million | -0.96pp |
| 2018-12-31 | 68.13% | $176.52 Million | $259.09 Million | +11.35pp |
| 2017-12-31 | 56.78% | $78.08 Million | $137.53 Million | -- |
About Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking … Read more